Diminished ovarian reserve (DOR)
Conditions
Interventions
Control group:Ursodeoxycholic Acid Capsules0.5g/day (0.25g/time, 2times/day) and Dimethyl fumarate 480mg/day (240mg/time, 2times/day)
Experimental group:Pig bile powder 0.6g/day (0.3g/time, 2times/day) and Dimethyl fumarate 480mg/day (240mg/time, 2times/day)
Sponsors
Hebei Maternity Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1.Previously undergone in vitro fertilization (IVF) treatment at our hospital. 2.Women aged 20 - 40 years who meet the diagnostic criteria for diminished ovarian reserve (DOR) or premature ovarian insufficiency (POI) (Spontaneous menstruation with AMH<=0.5, bilateral antral follicle count<=6); 3.Normal chromosomal karyotype. 4.No contraindications to the medications used in this study. 5.Normal hepatic and renal function. 6.Body mass index (BMI) < 30 kg/m^2.
Exclusion criteria
Exclusion criteria: 1.Infertile women whose infertility is not attributable to diminished ovarian function. 2.Women with severe cardiovascular, pulmonary, hepatic, or renal diseases; 3.Individuals with untreated sexually transmitted diseases (STDs) such as acquired immunodeficiency syndrome (AIDS), syphilis, Neisseria gonorrhoeae, or Chlamydia infections; 4.Women with a confirmed or suspected malignant tumor. 5.Women presenting with uterine organic pathologies such as uterine malformations, adenomyosis, uterine fibroids, endometrial hyperplasia; 6.Individuals with abnormal hepatic and renal function test results. 7.Women with chromosomal aberrations. 8.Patients currently receiving pharmacotherapy for other systemic diseases. 9.Participants currently enrolled in other clinical trials. 10.those with chronic conditions including diabetes mellitus, hypertension, hematological disorders, thrombotic diseases, autoimmune diseases, etc.; 11.those with comorbidities that pose a significant threat to patient safety or may impede the patient's ability to complete this study. 12.those with unresolved reproductive tract infectious diseases; 13.those with unremediated alcoholism, drug addiction, or substance abuse problems. 14.those with reproductive organ pathologies including hydrosalpinx or ovarian cysts.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Liver and kidney function; | — |
Primary
| Measure | Time frame |
|---|---|
| Ovarian indicators: ovarian volume, peak systolic velocity (PSV) and pulsatility index (PI) of ovarian artery blood flow, antral follicle count (AFC), and follicle size;Sex hormone six items - E2, P, FSH, LH, T, PRL;Anti-Müllerian hormone - AMH; | — |
Countries
China
Contacts
Public ContactKai Deng
Hebei Maternity Hospital
Outcome results
None listed